Background
==========

The International Stroke Trial (IST) was conducted between 1991 and 1996 (including the pilot phase between 1991 and 1993). It was a large, prospective, randomised controlled trial, with 100% complete baseline data and over 99% complete follow-up data. The aim of the trial was to establish whether early administration of aspirin, heparin, both or neither influenced the clinical course of acute ischaemic stroke \[[@B1]\].

Methods
=======

The study had a prospective, randomised, open treatment, blinded outcome (PROBE) design. The inclusion criteria were: clinical diagnosis of acute ischaemic stroke, with onset within the previous 48 hours and no clear indication for, or clear contraindication to, treatment with aspirin or subcutaneous heparin. Unlike many stroke trials of that era (and subsequently), the study did not set an upper age limit. Patients were to have a CT brain scan to confirm the diagnosis of stroke, and this was to be done before randomisation if at all possible. To enter a patient in the study, the clinician telephoned a central randomisation service (at the Clinical Trial Service Unit, Oxford) during this telephone call, the baseline variables were entered and checked, and once validated, the computer allocated the treatment and the telephonist then informed the clinician. The patients and treating clinicians were not blinded to the treatment given. Early outcome data were collected by the treating physician who completed a follow-up form at 14 days, death or hospital discharge (whichever occurred first). This form recorded data on events in hospital within 14 days, and the doctor\'s opinion on the final diagnosis of the initial event that led to randomisation. These unblinded data, may therefore be subject to some degree of bias. The primary outcome was the proportion of patients who were either dead or dependent on other people for activities of daily living at six months after randomisation. This outcome was collected by postal questionnaire mailed directly to the patient, or (in Italy) by telephone interview of the patient by a trained researcher, blinded to treatment allocation. The primary outcome was therefore assessed - as far as practicable - blind to treatment allocation and hence should be free from bias. We re-checked the data set for inaccuracies and inconsistencies and extracted data on the variables assessed at randomisation, and at the two outcome assessment points: at 14-days after randomisation, death or prior hospital discharge (whichever occurred first) and at 6-months.

Results
=======

Consent for publication of raw data was not obtained from participants. Consent for participation in the trial was obtained from all subjects or from an appropriate proxy, according to the procedures approved by relevant national and local hospital ethics committees (or Institutional Review Boards \[IRB\]). These patients were treated 15-20 years ago, and many have died. The dataset (see additional file [1](#S1){ref-type="supplementary-material"} - IST_data.csv) is fully anonymous in a manner that can easily be verified by any user of the dataset. Patients and hospitals are identified only by an anonymous code; there are no identifying data such as name, address or social security numbers; patient age has been rounded to the nearest whole number. In our view, publication of the dataset clearly presents no material risk to confidentiality of study participants.

The dataset includes the following baseline data: age, gender, time from onset to randomisation, presence or absence of atrial fibrillation (AF), aspirin administration within 3 days prior to randomisation, systolic blood pressure at randomisation, level of consciousness and neurological deficit. The deficits were classified as one of the Oxfordshire Community Stroke Project (OCSP) categories: total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), posterior circulation syndrome (POCS) and lacunar syndrome (LACS). We extracted events within 14 days on: the occurrence of recurrent stroke, pulmonary embolism, and death (date and cause of death). At 6 months we extracted: degree of recovery, place of residence and current use of antiplatelet or anticoagulant drugs and death (date and cause of death). The cause of death was classified as: due to initial stroke, recurrent ischaemic stroke, recurrent haemorrhagic stroke, pneumonia, coronary artery disease, pulmonary embolism, other vascular cause or a nonvascular cause. Patients were assigned to one of 6 categories according to the place of residence at 6 months following stroke: own home, relatives home, residential care, nursing home, other hospital departments or unknown. The variables extracted are listed with a brief description of each in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Nineteen thousand four hundred and thirty five patients from 467 hospitals in 36 countries were randomised within 48 hours of symptoms onset, of whom 13020 had a CT before randomisation, 5569 were first scanned after randomisation and 846 were not scanned at all. Five thousand one hundred thirty two (26.4%) were aged over 80 years at study entry. Given that 5569 patients were first scanned after randomisation, and 846 were not scanned at all, the \'final diagnosis\' is somewhat imprecise. However, since the analysis was by intention to treat, all participants were retained in the analysis, irrespective of the final diagnosis. The numbers of patients with each final diagnosis are given in Table [4](#T4){ref-type="table"}. Whilst the \'final diagnosis variable\' is of some interest, it may be influenced by events occurring after randomisation, so for any future analyses, the least biased assessment of the patient characteristics is that recorded at baseline, before randomisation.

###### 

Country codes used in International Stroke Trial.

  Country           Code
  ----------------- ------
  Albania           43
                    
  Argentina         29
                    
  Australia         01
                    
  Belgium           03
                    
  Brazil            42
                    
  Bulgaria          04
                    
  Canada            05
                    
  Chile             06
                    
  Czech Republic    07
                    
  Denmark           08
                    
  Ireland           09
                    
  Finland           10
                    
  France            11
                    
  Georgia           32
                    
  Germany           12
                    
  Greece            31
                    
  Hong Kong         30
                    
  Hungary           36
                    
  India             37
                    
  Indonesia         41
                    
  Israel            13
                    
  Italy             14
                    
  Japan             38
                    
  Latvia            39
                    
  Malaysia          40
                    
  Netherlands       15
                    
  New Zealand       16
                    
  Norway            17
                    
  Poland            18
                    
  Portugal          19
                    
  Romania           33
                    
  Singapore         34
                    
  Slovak Republic   44
                    
  Slovenia          20
                    
  South Africa      21
                    
  Spain             22
                    
  Sri Lanka         23
                    
  Sweden            24
                    
  Switzerland       25
                    
  Thailand          26
                    
  Turkey            35
                    
  UK                27
                    
  USA               28

###### 

Variables names and comments.

  Randomisation data                                                               
  -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HOSPNUM                                                                          Hospital number
                                                                                   
  RDELAY                                                                           Delay between stroke and randomisation in hours
                                                                                   
  RCONSC                                                                           Conscious state at randomisation (F - fully alert, D - drowsy, U - unconscious)
                                                                                   
  SEX                                                                              M = male; F = female
                                                                                   
  AGE                                                                              Age in years
                                                                                   
  RSLEEP                                                                           Symptoms noted on waking (Y/N)
                                                                                   
  RATRIAL                                                                          Atrial fibrillation (Y/N); not coded for pilot phase - 984 patients
                                                                                   
  RCT                                                                              CT before randomisation (Y/N)
                                                                                   
  RVISINF                                                                          Infarct visible on CT (Y/N)
                                                                                   
  RHEP24                                                                           Heparin within 24 hours prior to randomisation (Y/N)
                                                                                   
  RASP3                                                                            Aspirin within 3 days prior to randomisation (Y/N)
                                                                                   
  RSBP                                                                             Systolic blood pressure at randomisation (mmHg)
                                                                                   
  RDEF1                                                                            Face deficit (Y/N/C=can\'t assess)
                                                                                   
  RDEF2                                                                            Arm/hand deficit (Y/N/C=can\'t assess)
                                                                                   
  RDEF3                                                                            Leg/foot deficit (Y/N/C=can\'t assess)
                                                                                   
  RDEF4                                                                            Dysphasia (Y/N/C=can\'t assess)
                                                                                   
  RDEF5                                                                            Hemianopia (Y/N/C=can\'t assess)
                                                                                   
  RDEF6                                                                            Visuospatial disorder (Y/N/C=can\'t assess)
                                                                                   
  RDEF7                                                                            Brainstem/cerebellar signs (Y/N/C=can\'t assess)
                                                                                   
  RDEF8                                                                            Other deficit (Y/N/C=can\'t assess)
                                                                                   
  STYPE                                                                            Stroke subtype (TACS/PACS/POCS/LACS/OTH=other)
                                                                                   
  RDATE                                                                            Year and month of randomisation (yyyy-mm)
                                                                                   
  HOURLOCAL                                                                        Local time - hours (99-missing data) of randomisation
                                                                                   
  MINLOCAL                                                                         Local time - minutes (99-missing data) of randomisation
                                                                                   
  DAYLOCAL                                                                         Estimate of local day of week; 1 - Sunday, 2-Monday, 3-Tuesday, 4-Wednesday, 5-Thursday, 6-Friday, 7-Saturday
                                                                                   
  RXASP                                                                            Trial aspirin allocated (Y/N)
                                                                                   
  RXHEP                                                                            Trial heparin allocated (M/L/N). The terminology for the allocated dose of unfractioned heparin changed slightly from the pilot to the main study. Patients were allocated either 12500 units subcutaneously twice daily (coded as H in the pilot and M in the main trial), 5000 units twice daily (coded as L throughout) or to \'avoid heparin\' (coded as N throughout).
                                                                                   
  **Data collected on 14 day/discharge form about treatments given in hospital**   
                                                                                   
  DASP14                                                                           Aspirin given for 14 days or till death or discharge (Y/N/U=unknown)
                                                                                   
  DASPLT                                                                           Discharged on long term aspirin (Y/N/U=unknown)
                                                                                   
  DLH14                                                                            Low dose heparin given for 14 days or till death/discharge (Y/N/U=unknown)
                                                                                   
  DMH14                                                                            Medium dose heparin given for 14 days or till death/discharge (Y/N/U=unknown)
                                                                                   
  DHH14                                                                            Medium dose heparin given for 14 days etc in pilot (combine with above; Y/N)
                                                                                   
  ONDRUG                                                                           Estimate of time in days on trial treatment
                                                                                   
  DSCH                                                                             Non trial subcutaneous heparin (Y/N/U=unknown)
                                                                                   
  DIVH                                                                             Non trial intravenous heparin (Y/N/U=unknown)
                                                                                   
  DAP                                                                              Non trial antiplatelet drug (Y/N/U=unknown)
                                                                                   
  DOAC                                                                             Other anticoagulants (Y/N/U=unknown)
                                                                                   
  DGORM                                                                            Glycerol or manitol (Y/N/U=unknown)
                                                                                   
  DSTER                                                                            Steroids (Y/N/U=unknown)
                                                                                   
  DCAA                                                                             Calcium antagonists (Y/N/U=unknown)
                                                                                   
  DHAEMD                                                                           Haemodilution (Y/N/U=unknown)
                                                                                   
  DCAREND                                                                          Carotid surgery (Y/N/U=unknown)
                                                                                   
  DTHROMB                                                                          Thrombolysis (Y/N/U=unknown)
                                                                                   
  DMAJNCH                                                                          Major non-cerebral haemorrhage (Y/N/U=unknown)
                                                                                   
  DMAJNCHD                                                                         Date of above (days elapsed from randomisation)
                                                                                   
  DMAJNCHX                                                                         Comment on above
                                                                                   
  DSIDE                                                                            Other side effect (Y/N/U=unknown)
                                                                                   
  DSIDED                                                                           Date of above (days elapsed from randomisation)
                                                                                   
  DSIDEX                                                                           Comment on above
                                                                                   
  **Final diagnosis of initial event**                                             
                                                                                   
  DDIAGISC                                                                         Ischaemic stroke (Y/N/U=unknown)
                                                                                   
  DDIAGHA                                                                          Haemorrhagic stroke (Y/N/U=unknown)
                                                                                   
  DDIAGUN                                                                          Indeterminate stroke (Y/N/U=unknown)
                                                                                   
  DNOSTRK                                                                          Not a stroke (Y/N/U=unknown)
                                                                                   
  DNOSTRKX                                                                         Comment on above
                                                                                   
  **Recurrent stroke within 14 days**                                              
                                                                                   
  DRSISC                                                                           Ischaemic recurrent stroke (Y/N/U=unknown)
                                                                                   
  DRSISCD                                                                          Date of above (days elapsed from randomisation)
                                                                                   
  DRSH                                                                             Haemorrhagic stroke (Y/N/U=unknown)
                                                                                   
  DRSHD                                                                            Date of above (days elapsed from randomisation)
                                                                                   
  DRSUNK                                                                           Unknown type (Y/N/U=unknown)
                                                                                   
  DRSUNKD                                                                          Date of above (days elapsed from randomisation)
                                                                                   
  **Other events within 14 days**                                                  
                                                                                   
  DPE                                                                              Pulmonary embolism; (Y/N/U=unknown)
                                                                                   
  DPED                                                                             Date of above (days elapsed from randomisation)
                                                                                   
  DALIVE                                                                           Discharged alive from hospital (Y/N/U=unknown)
                                                                                   
  DALIVED                                                                          Date of above (days elapsed from randomisation)
                                                                                   
  DPLACE                                                                           Discharge destination (A-Home/B-Relatives home/C-Residential care/D-Nursing home/E-Other hospital departments/U-Unknown)
                                                                                   
  DDEAD                                                                            Dead on discharge form (Y/N/U=unknown)
                                                                                   
  DDEADD                                                                           Date of above (days elapsed from randomisation); NOTE: this death is not necessarily within 14 days of randomisation
                                                                                   
  DDEADC                                                                           Cause of death (1-Initial stroke/2-Recurrent stroke (ischaemic or unknown)/3-Recurrent stroke (haemorrhagic)/4-Pneumonia/5-Coronary heart disease/6-Pulmonary embolism/7-Other vascular or unknown/8-Non-vascular/0-unknown)
                                                                                   
  DDEADX                                                                           Comment on death
                                                                                   
  **Data collected at 6 months**                                                   
                                                                                   
  FDEAD                                                                            Dead at six month follow-up (Y/N/U=unknown)
                                                                                   
  FLASTD                                                                           Date of last contact (days elapsed from randomisation)
                                                                                   
  FDEADD                                                                           Date of death (days elapsed from randomisation); NOTE: this death is not necessarily within 6 months of randomisation
                                                                                   
  FDEADC                                                                           Cause of death (1-Initial stroke/2-Recurrent stroke (ischaemic or unknown)/3-Recurrent stroke (haemorrhagic)/4-Pneumonia/5-Coronary heart disease/6-Pulmonary embolism/7-Other vascular or unknown/8-Non-vascular/0-unknown)
                                                                                   
  FDEADX                                                                           Comment on death
                                                                                   
  FRECOVER                                                                         Fully recovered at 6 month follow-up (Y/N/U=unknown)
                                                                                   
  FDENNIS                                                                          Dependent at 6 month follow-up (Y/N/U=unknown)
                                                                                   
  FPLACE                                                                           Place of residance at 6 month follow-up (A-Home/B-Relatives home/C-Residential care/D-Nursing home/E-Other hospital departments/U-Unknown)
                                                                                   
  FAP                                                                              On antiplatelet drugs at six month follow-up (Y/N/U=unknown)
                                                                                   
  FOAC                                                                             On oral anticoagulants at six month follow-up (Y/N/U=unknown)
                                                                                   
  **Other data and derived variables**                                             
                                                                                   
  FU1_RECD                                                                         Date discharge form received (days elapsed from randomisation)
                                                                                   
  FU2_DONE                                                                         Date 6 month follow-up done (days elapsed from randomisation)
                                                                                   
  COUNTRY                                                                          Abbreviated country code
                                                                                   
  CNTRYNUM                                                                         Country code (see Table 1)
                                                                                   
  FU1_COMP                                                                         Date discharge form completed (days elapsed from randomisation)
                                                                                   
  NCCODE                                                                           Coding of compliance (see Table 3)
                                                                                   
  CMPLASP                                                                          Compliant for aspirin (N/Y)
                                                                                   
  CMPLHEP                                                                          Compliant for heparin (N/Y)
                                                                                   
  ID                                                                               Indicator variable for death (1 = died; 0 = did not die)
                                                                                   
  TD                                                                               Time of death or censoring in days
                                                                                   
  EXPDD                                                                            Predicted probability of death/dependence at 6 month
                                                                                   
  EXPD6                                                                            Predicted probability of death at 6 month
                                                                                   
  EXPD14                                                                           Predicted probability of death at 14 days
                                                                                   
  SET14D                                                                           Know to be dead or alive at 14 days (1 = Yes, 0 = No); this does not necessarily mean that we know outcome at 6 months - see OCCODE for this
                                                                                   
  ID14                                                                             Indicator of death at 14 days (1 = Yes, 0 = No)
                                                                                   
  OCCODE                                                                           Six month outcome (1-dead/2-dependent/3-not recovered/4-recovered/0 or 9 - missing status
                                                                                   
  **Indicator variables for specific causes of death**                             
                                                                                   
  DEAD1                                                                            Initial stroke (1 = Yes, 0 = No)
                                                                                   
  DEAD2                                                                            Reccurent ischaemic/unknown stroke (1 = Yes, 0 = No)
                                                                                   
  DEAD3                                                                            Reccurent haemorrhagic stroke (1 = Yes, 0 = No)
                                                                                   
  DEAD4                                                                            Pneumonia (1 = Yes, 0 = No)
                                                                                   
  DEAD5                                                                            Coronary heart disease (1 = Yes, 0 = No)
                                                                                   
  DEAD6                                                                            Pulmonary embolism (1 = Yes, 0 = No)
                                                                                   
  DEAD7                                                                            Other vascular or unknown (1 = Yes, 0 = No)
                                                                                   
  DEAD8                                                                            Non vascular (1 = Yes, 0 = No)
                                                                                   
  H14                                                                              Cerebral bleed/heamorrhagic stroke within 14 days; this is slightly wider definition than DRSH and is used for analysis of cerebral bleeds; (1 = Yes, 0 = No)
                                                                                   
  ISC14                                                                            Indicator of ischaemic stroke within 14 days (1 = Yes, 0 = No)
                                                                                   
  NK14                                                                             Indicator of indeterminate stroke within 14 days (1 = Yes, 0 = No)
                                                                                   
  STRK14                                                                           Indicator of any stroke within 14 days (1 = Yes, 0 = No)
                                                                                   
  HTI14                                                                            Indicator of haemorrhagic transformation within 14 days (1 = Yes, 0 = No)
                                                                                   
  PE14                                                                             Indicator of pulmonary embolism within 14 days (1 = Yes, 0 = No)
                                                                                   
  DVT14                                                                            Indicator of deep vein thrombosis on discharge form (1 = Yes, 0 = No)
                                                                                   
  TRAN14                                                                           Indicator of major non-cerebral bleed within 14 days (1 = Yes, 0 = No)
                                                                                   
  NCB14                                                                            Indicator of any non-cerebral bleed within 14 days (1 = Yes, 0 = No)

###### 

Provisional categories for non compliance (NCCODE).

  1\.     Should not have been randomised
  ------- -------------------------------------------
  2\.     Refused treatment
          
  3\.     Initial event not a stroke
          
  4\.     Haemorrhagic stroke
          
  5\.     Non compliers
          
  6\.     Discharged after 14 days
          
  7\.     Discharged up to 14 days
          
  8\.     Died prior to receiving the study drug(s)
          
  9\.     Died after receiving the study drug(s)
          
  10\.    Recurrent stroke/pulmonary embolism
          
  11\.    Clinical decision
          
   11a.   Suspected abnormality
          
   11b.   Withdrawn as dying
          
   11c.   Pre-existing condition
          
   11d.   Stated abnormal PTT
          
   11e.   Stated surgery
          
   11f.   Stated atrial fibrillation
          
  12\.    Administration problem
          
  13\.    Missed out more than 3 doses
          
  14\.    Side effect
          
   14a.   Refused treatment
          
   14b.   Discharged
          
   14c.   Administration problem
          
   14d.   Clinical decision
          
   14e.   Recurrent stroke
          
   14f.   Haemorrhagic stroke

###### 

Final diagnosis of initial event.

                                               Number
  -------------------------------------------- --------
  Ischaemic stroke                             17398
                                               
  Haemorrhagic stroke                          599
                                               
  Definite stroke, pathological type unknown   992
                                               
  Not a stroke                                 420
                                               
  Uncertain diagnosis                          26
                                               
  Total                                        19435

To restrict analyses to cases of definite ischaemic stroke, confirmed at the time of trial entry, the variable denoting whether CT had been performed before entry (RCT) should = Y and the final diagnosis should also be ischaemic (DDIAGISC=Y).

Please note that, in the original 1997 Lancet report on the trial \[[@B1]\], figures two a and two b reported the effects of allocation to aspirin and to heparin on the primary outcome, subdivided by various baseline characteristics and by the final diagnosis. The numbers of patients with each pathological type of stroke are somewhat different to the numbers above, because they relate to the number of patients with complete 6 month follow-up data, whereas the numbers above relate to all randomised patients.

Anonymisation
-------------

As recommended by *Hrynaszkiewicz et al.*\[[@B2]\] we have removed all direct and indirect identifiers from the database. We therefore present patient\'s age rounded to the nearest whole number of years. Time of admission to hospital (a potential identifier) was not recorded. Dates of events occurring post randomisation have been converted to the number of days from randomisation. The time variables that were recorded (see below) referred to time of randomisation in the trial (i.e. the time at which the system generated the treatment allocation), not time of admission to hospital, a variable, that - in our view - would not help identify the patient.

Discussion
==========

This large data set, with very complete follow-up, includes a very broad range of acute stroke patients with a uniquely large number of very elderly patients, and so may be useful to researchers planning future research studies. Users of the dataset should be aware that the study was conducted at a time when stroke unit care was not widely available and thrombolytic therapy was used rarely (and none of the included patients received it) \[[@B3]\]. Thus, the background stroke care for the included subjects, while not typical of present-day acute stroke care \[[@B4]\], is perhaps more typical of current stroke care in resource poor settings \[[@B5]\]. Given that the developing world faces a future epidemic of non-communicable diseases, including stroke \[[@B5]\], these data may therefore prove particularly valuable for planning future trials in resource-poor settings. In the developed world, the proportion of the general population who are \'very elderly\' is rapidly increasing. Older people have been substantially under-represented in stroke trials to date \[[@B6]\], so we hope the large number of patients aged over 80 in this data set could also facilitate planning of trials in the \'older old\'.

The publication of raw datasets such as the IST\'s may offer wholly unanticipated benefits to the wider research community. For example, the dataset was licensed to an independent statistical group who used the data to estimate the size and direction of biases introduced when non-randomised comparisons were made and the differences between direct and indirect comparisons. This empirical work led to two important publications on the topic \[[@B7],[@B8]\]. Such additional benefits, realised long after the original trial was completed, are a further clear indication of the value of opening access to such datasets.
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